IntelliPlex Lung Cancer Panel - FFPE DNA

Blood test panel for detecting and characterizing genetic and epigenetic mutations in circulating tumor DNA. Helps determine cancer origin, measure tumor burden, and identify new mutations during targeted therapy treatment.

High-throughput sequencing detection service for tumor-derived circulating free DNA genetic mutations, enabling precise tumor profiling and monitoring. The service has passed national inter-laboratory quality assessments with full marks.

Molecular diagnostic assay utilizing circulating tumor cell and cell-free DNA analysis to support pulmonary nodule characterization and malignancy risk assessment.

A molecular diagnostic test utilizing DNA methylation technology for early detection of lung cancer. Enables risk assessment and early diagnosis of lung malignancies through liquid biopsy methodology.

CRISPincette MultiCancer is an in vitro diagnostic test utilizing ultra-precision CRISPR/Cas9 technology for liquid biopsy-based cancer detection. The assay selectively cleaves wild-type DNA while amplifying target mutant sequences, enabling sensitive identification of circulating tumor DNA across multiple cancer types.

A specialized molecular diagnostic test for early detection and risk assessment of pancreatic cancer using DNA methylation technology. Supports early diagnosis of this highly aggressive malignancy.

A DNA methylation-based molecular diagnostic test designed for early detection and risk assessment across multiple cancer types. The test utilizes proprietary methylation technology to identify cancer signals in biological samples.

Custom NGS panels for targeted resequencing using Cell3 Target technology to convert cell-free DNA (cfDNA), genomic DNA (gDNA), and formalin-fixed paraffin-embedded (FFPE) DNA into libraries for next-generation sequencing. The panels are validated for ctDNA, gDNA, and FFPE DNA samples for oncology applications including early cancer detection and cancer monitoring. They incorporate error suppression technology with unique molecular indexes (UMIs) and unique dual indexes (UDIs) to enable confident variant calling down to 0.1% VAF, with support for as little as 1 ng of genomic or cfDNA input and 10 ng of FFPE material.

A liquid biopsy diagnostic test for detection of EGFR mutations in circulating tumor DNA, supporting non-invasive lung cancer monitoring and treatment selection.

A diagnostic kit based on GENETRON's proprietary 'one-step method' technology enabling completion of library construction in 1.5 to 3 hours (China patent ZL 201710218529.4). It detects EGFR, KRAS, BRAF, HER2, and PIK3CA gene mutations in DNA and ALK and ROS1 gene fusions in RNA from FFPE tissue samples of non-small cell lung cancer patients, as well as MET gene 14 exon skipping mutations.

QLoci-based assay panel for non-invasive prenatal testing that identifies and quantitates fetal cell-free DNA (cfDNA) fragments. Provides genetic screening with minimal sample requirements and high sensitivity.

Specialized NGS panel for lung cancer genomics and clinical diagnostics. Delivers targeted genetic profiling for oncology applications in pulmonary disease.